drugset / Trial / NCT01004315

A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder

NCT01004315

Phase 3 Completed 750 enrolled Kissei Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritobegron Small molecule
Comparator Tolterodine Small molecule

Indications